One Amgen Center Drive
At Amgen, our mission—to serve patients—drives all that we do. This sense of shared purpose has allowed us to become one of the world’s leading biotechnology companies as we continue to launch new medicines at unprecedented rates and reach millions of patients worldwide.
We collaborate with world-class talent, utilize the industry’s largest toolkit of modalities, and leverage industry-leading partnerships and state-of-the-art technology to develop new processes and products that can turn the tide of serious, life-interrupting illnesses.
As a values-based organization, we aim to make a positive impact on the world. From investments in education to inspire future generations of scientists, to rewarding our colleagues with robust family-centered benefits, we believe in making a difference in the lives of our patients, staff and communities.
At Amgen, we believe in the power of tomorrow and it shows.
Discover what Amgen can do for you by visiting careers.amgen.com.
For more information, visit
www.amgen.com, LinkedIn and follow us on www.twitter.com/amgencareers.
Tweets by Amgen
The Amgen Difference
2071 articles with Amgen
Amgen announced voting results from the Company's Annual Meeting of Stockholders on May 20, 2020, held virtually this year due to the COVID-19 pandemic.
Updated Data Evaluating Sotorasib (AMG 510), a First-in-Class Investigational KRASG12C Inhibitor, in Colorectal Cancer and Other Solid Tumors
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Virtual Global Healthcare Conference at 1:40 p.m. ET on Thursday , May 14. Peter H. Griffith , executive vice president and chief financial officer, and Murdo Gordon , executive vice president of Global Commercial Operations at Amgen will present. Live
Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv m
Amgen Announces Positive Top-Line Results From Otezla® (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis
Otezla Treatment Resulted in Significant Improvements in Measures of Mild-to-Moderate Psoriasis Compared With Placebo Data Will be Submitted to the U.S. Food and Drug Administration (FDA) for Inclusion in Otezla Prescribing Information
Amgen today announced that the U.S. District Court in Delaware issued a decision upholding the validity of patent claims from three patents that protect Amgen's multiple myeloma therapy KYPROLIS®.
Amgen (NASDAQ:AMGN) today announced that the Company will participate in the SunTrust Robinson Humphrey Life Sciences Summit Virtual Meeting Series. David M. Reese, M.D., executive vice president of Research and Development at Amgen, is scheduled to participate on Wednesday, May 6 at 11:00 a.m. PT (2:00 p.m. ET).
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2020 and discussed the company's response to the COVID-19 pandemic.
Amgen announced that it will report its first quarter financial results on Thursday, April 30, 2020, after the close of the U.S. financial markets.
Amgen Canada Inc. announced a range of initiatives to give donations, supplies and expertise to help Canadian communities fight the challenges presented by COVID-19.
Amgen (NASDAQ:AMGN) and Adaptive Biotechnologies Corporation (NASDAQ:ADPT) will participate in a webinar hosted by Bernstein on Thursday, April 9 at 8 a.m. PT (11 a.m. ET) where David M. Reese, M.D., executive vice president of Research and Development at Amgen and Harlan Robins, PhD, chief scientific officer and co-founder at Adaptive,
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
Adaptive Extends Immune Medicine Platform to Discover Therapeutic Antibodies From Recovered COVID-19 Patients Amgen Will Leverage Genetics, Immunology, Antibody Engineering and Manufacturing Capabilities Companies Will Begin Work Immediately
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
Amgen K.K. Will Focus on Bringing Amgen's Full Global Pipeline to Japanese Patients.
As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 31, 2020.
Like many biopharma companies, Amgen is evaluating how the COVID-19 pandemic is affecting its operations, supply chain and clinical trial programs.
Amgen Announces Positive Results At ACC.20/WCC From Phase 3B Study Of Repatha® (Evolocumab) In People Living With HIV Who Have High LDL-Cholesterol
Study Met Primary Endpoint (Change From Baseline in LDL-C) and All Secondary Endpoints Repatha is the First PCSK9 Inhibitor to Demonstrate LDL-C Lowering Results in People Living with HIV [28-March-2020] THOUSAND OAKS, Calif. , March 28, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the Evolocuma B E ffect on LDL-C Lower I
A summary of daily biopharma industry news. Please check out stories that are trending on March 27, 2020.